245 related articles for article (PubMed ID: 37728865)
1. Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.
Nie T; Heo YA; Shirley M
Drugs; 2023 Oct; 83(15):1425-1432. PubMed ID: 37728865
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
Adams D; Tournev IL; Taylor MS; Coelho T; Planté-Bordeneuve V; Berk JL; González-Duarte A; Gillmore JD; Low SC; Sekijima Y; Obici L; Chen C; Badri P; Arum SM; Vest J; Polydefkis M;
Amyloid; 2023 Mar; 30(1):1-9. PubMed ID: 35875890
[TBL] [Abstract][Full Text] [Related]
3. Vutrisiran: First Approval.
Keam SJ
Drugs; 2022 Sep; 82(13):1419-1425. PubMed ID: 35997942
[TBL] [Abstract][Full Text] [Related]
4. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Merkel M; Danese D; Chen C; Wang J; Wu A; Yang H; Lin H
Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
[TBL] [Abstract][Full Text] [Related]
5. Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy.
Planté-Bordeneuve V; Perrain V
Expert Opin Drug Discov; 2024 Apr; 19(4):393-402. PubMed ID: 38281068
[TBL] [Abstract][Full Text] [Related]
6. Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy.
Obici L; Ajroud-Driss S; Lin KP; Berk JL; Gillmore JD; Kale P; Koike H; Danese D; Aldinc E; Chen C; Vest J; Adams D;
Neurol Ther; 2023 Oct; 12(5):1759-1775. PubMed ID: 37523143
[TBL] [Abstract][Full Text] [Related]
7. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L
Coelho T; Ando Y; Benson MD; Berk JL; Waddington-Cruz M; Dyck PJ; Gillmore JD; Khella SL; Litchy WJ; Obici L; Monteiro C; Tai LJ; Viney NJ; Buchele G; Brambatti M; Jung SW; St L O'Dea L; Tsimikas S; Schneider E; Geary RS; Monia BP; Gertz M
Neurol Ther; 2021 Jun; 10(1):375-389. PubMed ID: 33638113
[TBL] [Abstract][Full Text] [Related]
8. Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Garcia-Pavia P; Grogan M; Kale P; Berk JL; Maurer MS; Conceição I; Di Carli M; Solomon SD; Chen C; Yureneva E; Vest J; Gillmore JD
Eur J Heart Fail; 2024 Feb; 26(2):397-410. PubMed ID: 38321786
[TBL] [Abstract][Full Text] [Related]
9. A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Olatunji G; Kokori E; Abraham IC; Omoworare O; Olatunji D; Ezeano C; Emmanuel Adeoba B; Stanley AC; Oluwatobiloba AM; Oluwademilade OB; Shimelis KM; Olanisa O; Aderinto N
Medicine (Baltimore); 2024 Jun; 103(26):e38767. PubMed ID: 38941378
[TBL] [Abstract][Full Text] [Related]
10. Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
Zhang X; Goel V; Attarwala H; Sweetser MT; Clausen VA; Robbie GJ
J Clin Pharmacol; 2020 Jan; 60(1):37-49. PubMed ID: 31322739
[TBL] [Abstract][Full Text] [Related]
11. Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.
Titze-de-Almeida SS; Brandão PRP; Faber I; Titze-de-Almeida R
Mol Diagn Ther; 2020 Feb; 24(1):49-59. PubMed ID: 31701435
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.
Brannagan TH; Coelho T; Wang AK; Polydefkis MJ; Dyck PJ; Berk JL; Drachman B; Gorevic P; Whelan C; Conceição I; Plante-Bordeneuve V; Merlini G; Obici L; Plana JMC; Gamez J; Kristen AV; Mazzeo A; Gentile L; Narayana A; Olugemo K; Aquino P; Benson MD; Gertz M;
J Neurol; 2022 Dec; 269(12):6416-6427. PubMed ID: 35908242
[TBL] [Abstract][Full Text] [Related]
13. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
Obici L; Berk JL; González-Duarte A; Coelho T; Gillmore J; Schmidt HH; Schilling M; Yamashita T; Labeyrie C; Brannagan TH; Ajroud-Driss S; Gorevic P; Kristen AV; Franklin J; Chen J; Sweetser MT; Wang JJ; Adams D
Amyloid; 2020 Sep; 27(3):153-162. PubMed ID: 32131641
[No Abstract] [Full Text] [Related]
14. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams D; Polydefkis M; González-Duarte A; Wixner J; Kristen AV; Schmidt HH; Berk JL; Losada López IA; Dispenzieri A; Quan D; Conceição IM; Slama MS; Gillmore JD; Kyriakides T; Ajroud-Driss S; Waddington-Cruz M; Mezei MM; Planté-Bordeneuve V; Attarian S; Mauricio E; Brannagan TH; Ueda M; Aldinc E; Wang JJ; White MT; Vest J; Berber E; Sweetser MT; Coelho T;
Lancet Neurol; 2021 Jan; 20(1):49-59. PubMed ID: 33212063
[TBL] [Abstract][Full Text] [Related]
15. Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management.
Alcantara M; Mezei MM; Baker SK; Breiner A; Dhawan P; Fiander A; Fine NM; Hahn C; Katzberg HD; Khayambashi S; Massie R; Matte G; Putko B; Siddiqi Z; Delgado D; Bril V
Can J Neurol Sci; 2022 Jan; 49(1):7-18. PubMed ID: 33631091
[TBL] [Abstract][Full Text] [Related]
16. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
Gertz MA; Scheinberg M; Waddington-Cruz M; Heitner SB; Karam C; Drachman B; Khella S; Whelan C; Obici L
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):701-711. PubMed ID: 31268366
[No Abstract] [Full Text] [Related]
17. Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation.
Badri P; Habtemariam B; Melch M; Clausen VA; Arum S; Li X; Jay PY; Vest J; Robbie GJ
Clin Pharmacokinet; 2023 Oct; 62(10):1509-1522. PubMed ID: 37639169
[TBL] [Abstract][Full Text] [Related]
18. Impact of Baseline Neuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study.
Luigetti M; Quan D; Berk JL; Conceição I; Misumi Y; Chao CC; Bender S; Aldinc E; Vest J; Adams D
Neurol Ther; 2024 Jun; 13(3):625-639. PubMed ID: 38512694
[TBL] [Abstract][Full Text] [Related]
19. Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
Skrahina V; Grittner U; Beetz C; Skripuletz T; Juenemann M; Krämer HH; Hahn K; Rieth A; Schaechinger V; Patten M; Tanislav C; Achenbach S; Assmus B; Knebel F; Gingele S; Skrahin A; Hartkamp J; Förster TM; Roesner S; Pereira C; Rolfs A
Ann Med; 2021 Dec; 53(1):1787-1796. PubMed ID: 34658264
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
